Gender-associated differences of lung cancer and mechanism

Chinese Journal of Lung Cancer

Volumn 14, Issue 7, 2011, Pages 625-630

  Xing, Xin ^a,b   Liao, Yongde ^a   Tang, Hexiao ^a   Chen, Guang ^a   Ju, Sheng ^a   You, Liangkun ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Difference; Gender; Lung neoplasms

Indexed keywords

ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CANCER THERAPY; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; OUTCOME ASSESSMENT; PROGNOSIS; SEX DIFFERENCE;

HUMANS; LUNG NEOPLASMS; SEX FACTORS;

EID: 79960582840     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2011.07.12     Document Type: Article

References (62)

1. Yang L, Li Ld, Chen Yd, et al. Mortality time trends and the incidence and mortality estimation and projection for lung cancer in China. Chin J Lung Cance, 2005, 8(4): 274-278.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin, 2010, 60(5): 277-300.
3. Yang GH, Wang JF, Wan X, et al. Quantitative analysis of factors affected mortality trend in Chinese. Chin J Epidemiol, 2005, 26(12): 3212-3218.
4. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival: Population-based study of 20,561 cases. Ann Oncol, 2002, 13(7): 1087-1093.
5. Crespo-Leiro MG, Villa-Arranz A, Manito-Lorite N, et al. Lung cancer after heart transplantation: results from a large multicenter registry. Am J Transplant, 2011, 11(5): 1035-1040.
6. Yao XQ, Sun SL, Liu P, et al. Characteristics of distribution in 1,213 cases of lung cancer. J Occupational Health and Damage, 2008, 18(1): 9-10.
7. Kligerman S, White C. Epidemiology of lung cancer in women: risk factors,survival, and screening. AJRAmJ Roentgenol, 2011, 196(2): 287-295.
8. Chen K, Wang PP, Sun B, et al. Twenty year secular changes in sex specific lung cancer incidence rates in an urban Chinese population. Lung Cancer, 2006,51(1): 13-19.
9. International Early Lung Cancer Action Program Investigators, Henschke CI, Yip R, et al. Women's susceptibility to tobacco carcinogens and survival after diagnosis oflung cancer. JAMA, 2006,296(2): 180-184.
10. Tse LA, Mang OW, Yu IT, et al. Cigarette smoking and changing trends of lung cancer incidence by histological subtype among Chinese male population. Lung Cancer, 2009, 66(l): 22-27.
11. Liu SP, Zhang Y Gender-associated differences in clinical characteristics of patients with primary lung cancer. Chin J Geriatric Care, 2008, 6(4): 18-20
12. Ramanakumar AV Parent ALE, Siemiatycki J. Risk oflung cancer from residential heating and cook fuels in Montreal, Canada. Am J Epidemiol, 2007, 165(6): 634-642.
13. Nitadori J, Inoue M, Iwasaki M, et al. Association between lung cancer incidence and family history oflung cancer: data from a large-scale population-based cohort study, the JPHC study. Chest, 2006, 130(4): 968-975.
14. Minami H, Yoshimura M, Matsuoka H, et al. Lung cancer treated surgically in patients <50 years of age. Chest, 2001, 120(l): 32-36.
15. Cerfolio RJ, Bryant AS, Scott E, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest, 2006, 130(6): 1796-1802.
16. Devesa SS, Bray F, Vizcaino AP, et al. International lung cancer trends by histologic type: Male:Female differences diminishing and adenocarcinoma rates rising. IntJ Cancer, 2005, 117(2): 294-299.
17. Alberg AJ, Brock MV, Samet JM. Epidemiology oflung cancer: looking to the future. J Clin Oncol, 2005, 23(14): 3175-3185.
18. Chen F, Bina WF, Cole P. Declining incidence rate oflung adenocarcinoma in the United States. Chest, 2007, 131(4): 1000-1005.
19. Wang JF, Huang CY, Li SH. Research progress on dietary fat and the development oflung cancer. J Hygiene Res, 2004, 33(3): 383-385.
20. Keller SM, Vangel MG, Adak S, et al. The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and Ilia non-small cell lung cancer. Lung Cancer, 2002, 37(3): 303-309.
21. Yamamoto H, Sekine I, Yamada K, et al. Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel. Oncology, 2008, 75(3-4): 169-174.
22. Sekine I, Sumi M, Ito Y, et al. Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemo-radiotherapy.Jpnj Clin Oncol, 2009, 39(ll): 707-712.
23. Tanaka T, Matsuoka M, Sutani A, et al. Frequency of and variables associated with the EGFR mutation and its subtypes. IntJ Cancer, 2010, 126(3): 651-655.
24. Tamura K, Fukuoka M. Gefitinib in non-small cell lung cancer. Expert OpinPharmacother, 2005, 6(6): 985-993.
25. Asamura H, Goya T, Koshiishi Y, et al. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol, 2008, 3(1): 46-52.
26. Shi MX, Xu GZ, Gao J, et al. Sex effect on prognosis after lung cancer operation. Mod Oncol, 2004, 12(l): 36-37.
27. Doning JS, Le QT, Wakelee HA. Lung cancer in women: Exploring sex differences in susceptibility, biology, and therapeutic response. Clin Lung Cancer, 2006, 8(1): 22-29.
28. Jubelirer SJ, Varela NL, Welch CA, et al. Does sex make a difference in survival of patients undergoing resection for early stage non-small cell lung cancer (NSCLC)?WVMedJ, 2009, 105(4): 18-22.
29. Cao HC, Chen JK, Stewart J, et al. Distribution of p53 and K-ras mutation in human lung cancer tissues. Carcinogenesis, 1997, 18(3): 473-478.
30. Vahakankangas KH, Bennett WP, Castren K, et al. p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res, 2001, 61(11): 4350-4356.
31. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer, 2001, 92(6): 1525-1530.
32. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science, 2001, 293(5532): 1068-1070.
33. Wu JY, Wang J, Lai JC, et al. Association of 06-methylguanine-DNA meth-yltransferase (MGMT) promoter methylation with p53 mutation occurrence non-small cell lung cancer with different histology, gender, and smoking status. Ann Surg Oncol, 2008, 15(ll): 3272-3277.
34. Kiyohara C, Yoshimasu K, Takayama K, et al. Lung cancer susceptibility: are we on our way to identifying a high-risk group? Future Oncol, 2007, 3(6): 617-627.
35. Alexandrie AK, Sundberg MI, Seidegard J, et al. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis, 1994, 15(9): 1785-1790.
36. Tang DL, Rundle A, Warburton D, et al. Associations between both genetic and environmental biomarkers and lung cancer: evidence of a greater risk of lung cancer in women smokers. Carcinogenesis, 1998, 19(ll): 1949-1953.
37. Kriek E, Rojas M, Alexandrov K, et al. Polycyclic aromatic hydrocarbon-DNA adducts in humans: relevance as biomarkers for exposure and cancer risk. Mutat Res, 1998, 400(1-2): 215-231.
38. Kure EH, Ryberg D, Hewer A, et al. p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis, 1996, 17(10): 2201-2205.
39. Liu Y, Inoue M, Sobue T, et al. Reproductive factors, hormone use and the risk oflung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study IntJ Cancer, 2005, 117(4): 662-666.
40. Weinberg OK, Marquez-Garban DC, Fishbein MC, et al. Aromatase inhibitors in human lung cancer therapy. Cancer Res, 2005, 65(24): 11287-11291.
41. Niikawa H, Suzuki T, Miki Y, et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res, 2008, 14(14): 4417-4426.
42. Hammoud Z, Tan B, Badve S, et al. Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr Relat Cancer, 2008, 15(2): 475-483.
43. Ivanova MM, Mazhawidza W, Dougherty SM, et al. Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells. Am J Respir Cell Mol Biol, 2010, 42(3): 320-330.
44. Schwartz AG, Prysak GM, Murphy V, et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res, 2005, 11(20): 7280-7287.
45. Wu CT, Chang YL, ShihJY, et al. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg, 2005, 130(4): 979-986.
46. Kawai H, Ishii A, Washiya K, et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res, 2005, 11(14): 5084-5089.
47. Shaaban AM, Green AR, Karthik S, et al. Nuclear and cytoplasmic expression of ERbetal, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res, 2008, 14(16): 5228-5235.
48. Yan M, Rayoo M, Takano EA, et al. Nuclear and cytoplasmic expressions of ERbetal and ERbeta2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Res Treat, 2011, 126(2): 395-405.
49. Leung YK, Mak P, Hassan S, et al. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci USA, 2006, 103(35): 13162-13167.
50. Rago V, Romeo F, Giordano F, et al. Identification of ERbetal and ERbeta2 in human seminoma, in embryonal carcinoma and in their adjacent intratu-bular germ cell neoplasia. Reprod Biol Endocrinol, 2009, 7: 56.
51. Ryk C, Kumar R, Thirumaran RK, et al. Polymorphisms in the DNA repair genes XRCC1, APEX1, XRCC3 and NBS1, and the risk for lung cancer in never-and ever smokers. Lung Cancer, 2006, 54(3): 258-292.
52. Divine KK, Gilliland FD, Crowell RE, et al. The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung. Mutat Res, 2001, 461 (4): 273-278.
53. Dresler CM, Fratelli C, Babb J, et al. Gender differences in genetic susceptibility for lung cancer. Lung Cancer, 2000, 30(3): 153-160.
54. Mollerup S, Ryberg D, Hewer A, et al. Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res, 1999, 59(14): 3317-3320.
55. Yang XR, Wacholder S, Xu Z, et al. CYP1A1 polymorphism in relation to lung cancer in Chinese women. Cancer Lett, 2004, 214(2): 197-204.
56. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-1500.
57. Xia XY, Maynr.niyaz. Progression of the relationship between HPV and HLA in uterine cervix cancer. Mod Biomed Prog, 2010, 10(8): 1566-1569.
58. Syrjanen KJ. HPV infections and lung cancer. J Clin Pathol, 2002, 55(12): 885-891.
59. Willey JC, Broussoud A, Sleemi A, et al. Immortalization of normalhuman-bronchial epithelial cells by human papillomaviruses 16 or 18. Cancer Res, 1991, 51(19): 5370-5377.
60. Li YJ, Tsai YC, Chen YC, et al. Human papilloma virus and female lung adenocarcinoma. Semin Oncol,2009, 36(6): 542-552.
61. Iwakawa R, Kohno T, Enari M, et al. Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma. Cancer Sci,2010, 101(8): 1891-1896.
62. Wu JY, Yu CJ, Yang CH, et al. First or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. Am J Respir Crit Care Med, 2008, 178(8): 847-853.